Vertex Pharmaceuticals Inc (VRTX)
450.37
-0.86
(-0.19%)
USD |
NASDAQ |
Nov 21, 16:00
450.38
+0.01
(+0.00%)
After-Hours: 20:00
Vertex Pharmaceuticals Enterprise Value: 109.46B for Nov. 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 21, 2024 | 109.46B |
| November 20, 2024 | 109.68B |
| November 19, 2024 | 108.85B |
| November 18, 2024 | 113.74B |
| November 15, 2024 | 113.41B |
| November 14, 2024 | 118.11B |
| November 13, 2024 | 120.85B |
| November 12, 2024 | 119.66B |
| November 11, 2024 | 122.68B |
| November 08, 2024 | 126.55B |
| November 07, 2024 | 122.87B |
| November 06, 2024 | 120.60B |
| November 05, 2024 | 122.21B |
| November 04, 2024 | 115.24B |
| November 01, 2024 | 114.80B |
| October 31, 2024 | 116.05B |
| October 30, 2024 | 115.92B |
| October 29, 2024 | 114.71B |
| October 28, 2024 | 116.25B |
| October 25, 2024 | 116.60B |
| October 24, 2024 | 115.11B |
| October 23, 2024 | 114.63B |
| October 22, 2024 | 115.88B |
| October 21, 2024 | 116.70B |
| October 18, 2024 | 117.96B |
| Date | Value |
|---|---|
| October 17, 2024 | 122.02B |
| October 16, 2024 | 119.06B |
| October 15, 2024 | 118.30B |
| October 14, 2024 | 118.43B |
| October 11, 2024 | 117.63B |
| October 10, 2024 | 116.20B |
| October 09, 2024 | 114.09B |
| October 08, 2024 | 111.76B |
| October 07, 2024 | 109.10B |
| October 04, 2024 | 110.83B |
| October 03, 2024 | 110.37B |
| October 02, 2024 | 112.59B |
| October 01, 2024 | 114.55B |
| September 30, 2024 | 113.35B |
| September 27, 2024 | 113.67B |
| September 26, 2024 | 113.74B |
| September 25, 2024 | 113.39B |
| September 24, 2024 | 113.70B |
| September 23, 2024 | 112.93B |
| September 20, 2024 | 114.20B |
| September 19, 2024 | 117.55B |
| September 18, 2024 | 116.59B |
| September 17, 2024 | 118.42B |
| September 16, 2024 | 120.53B |
| September 13, 2024 | 119.48B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
38.39B
Minimum
Oct 05 2021
126.55B
Maximum
Nov 08 2024
69.34B
Average
64.70B
Median
Oct 20 2022
Enterprise Value Benchmarks
| Gilead Sciences Inc | 129.99B |
| Eli Lilly and Co | 739.59B |
| Bristol-Myers Squibb Co | 159.82B |
| Moderna Inc | 7.852B |
| Pfizer Inc | 199.35B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 1.045B |
| Revenue (Quarterly) | 2.772B |
| Total Expenses (Quarterly) | 1.640B |
| EPS Diluted (Quarterly) | 4.01 |
| Gross Profit Margin (Quarterly) | 85.84% |
| Profit Margin (Quarterly) | 37.71% |
| Earnings Yield | -0.44% |
| Operating Earnings Yield | 3.62% |
| Normalized Earnings Yield | 2.626 |